---
schema_version: "secwatch.filing_event.v1"
accession: "0001759138-26-000010"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:23:01.328982+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q4/FY2025 cash $133.6M; myositis BLA on track for 2027; $30M raise

## Summary
- Q4 R&D expenses $36.2M, FY R&D $142.7M; cash $133.6M as of Dec 31, 2025; raised additional $30M in Q1 2026.
- Registrational DM/ASyS cohort enrolling (17 patients); BLA submission for rese-cel in myositis targeted for 2027.
- No-preconditioning rese-cel data from RESET-SLE expected 1H26 (initial) and 2H26 (durability); PV durability data throughout 2026.
- Automated manufacturing with Cellares: initial clinical data expected 1H26; potential to produce for thousands per year.
- Complete Phase 1/2 data from RESET-SSc, RESET-SLE, RESET-MG to be presented in 1H26; design updates for SSc in 1H26 and MG mid-2026.

## SEC filing metadata
- accession: 0001759138-26-000010
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/0001759138-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/caba-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759138-26-000010
- JSON: https://secwatch.observer/filing/0001759138-26-000010.json
- Plain text: https://secwatch.observer/filing/0001759138-26-000010.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 23, 2026, Cabaletta Bio, Inc. (the "Company") announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/0001759138-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.